The adapted Zelen was a feasible design to trial exercise in myeloma survivors

Joanne Land, Orla McCourt, Malgorzata Heinrich, Rebecca J Beeken, Dimitrios A Koutoukidis, Bruce Paton, Kwee Yong, Allan Hackshaw, Abigail Fisher, Joanne Land, Orla McCourt, Malgorzata Heinrich, Rebecca J Beeken, Dimitrios A Koutoukidis, Bruce Paton, Kwee Yong, Allan Hackshaw, Abigail Fisher

Abstract

Objectives: We used a method rarely seen in cancer behavioral trials to explore methods of overcoming difficulties often seen in randomized controlled trials. We report our experiences of the adapted Zelen design, so that other researchers can consider this approach for behavioral trials.

Study design and setting: The adapted Zelen design was used to explore the effects of exercise on multiple myeloma patients fatigue, quality of life, and physical outcomes. All participants consented to an observational cohort study of lifestyle factors but were unaware of subsequent randomization to remain in cohort only group or be offered an exercise intervention requiring second consent.

Results: There was lower than expected uptake to the exercise offered group (57%), so the length of recruitment increased from 24 to 29 months to ensure power was reached. At enrollment, patients were unaware of the potential increased commitment, and as a result, 62% of participants allocated to the intervention declined because of the extra time/travel commitment required. This emulates clinical settings and suggests improvements in intervention delivery are required. Our findings suggest that the adapted Zelen design may be useful in limiting dropout of controls due to dissatisfaction from group allocation, or contamination of control arm.

Conclusion: Future use of this design warrants careful consideration of the study resources and recruitment time frames required but holds potential value in reducing contamination, control group dissatisfaction, and resulting dropout. Adapted Zelen design reduces selection bias and therefore gives clinicians a better understanding of acceptability in clinical settings. Future studies should evaluate control group experiences of the design and formally record contamination throughout the study to confirm its acceptability.

Keywords: Exercise; Exercise-oncology; Multiple myeloma; Physical activity; Post randomization consent; Research design.

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Flow of participants through the double consent process.

References

    1. Foster N., Little P. Methodological issues in pragmatic trials of complex interventions in primary care. Br J Gen Pract. 2012;62:10–11.
    1. King M., Nazareth I., Lampe F., Bower P., Chandler M., Morou M. Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA. 2005;293:1089–1099.
    1. Featherstone K., Donovan J.L. Why don't they just tell me straight, why allocate it?" The struggle to make sense of participating in a randomised controlled trial. Soc Sci Med. 2002;55:709–719.
    1. Courneya K.S., Friedenreich C.M., Quinney H.A., Fields A.L., Jones L.W., Fairey A.S. A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care (Engl) 2003;12:347–357.
    1. Smith L., Croker H., Fisher A., Williams K., Wardle J., Beeken R.J. Cancer survivors' attitudes towards and knowledge of physical activity, sources of information, and barriers and facilitators of engagement: a qualitative study. Eur J Cancer Care (Engl) 2017;26
    1. Velthuis M.J., May A.M., Monninkhof E.M., van der Wall E., Peeters P.H. Alternatives for randomization in lifestyle intervention studies in cancer patients were not better than conventional randomization. J Clin Epidemiol. 2012;65:288–292.
    1. Steins Bisschop C.N., Courneya K.S., Velthuis M.J., Monninkhof E.M., Jones L.W., Friedenreich C. Control group design, contamination and drop-out in exercise oncology trials: a systematic review. PLoS One. 2015;10:e0120996.
    1. Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979;300:1242–1245.
    1. Adamson J., Cockayne S., Puffer S., Torgerson D.J. Review of randomised trials using the post-randomised consent (Zelen's) design. Contemp Clin Trials. 2006;27:305–319.
    1. Schellings R., Kessels A.G., ter Riet G., Knottnerus J.A., Sturmans F. Randomized consent designs in randomized controlled trials: systematic literature search. Contemp Clin Trials. 2006;27:320–332.
    1. Campbell R., Peters T., Grant C., Quilty B., Dieppe P. Adapting the randomized consent (Zelen) design for trials of behavioural interventions for chronic disease: feasibility study. J Health Serv Res Policy. 2005;10:220–225.
    1. Velthuis M.J., May A.M., Koppejan-Rensenbrink R.A., Gijsen B.C., van Breda E., de Wit G.A. Physical Activity during Cancer Treatment (PACT) study: design of a randomised clinical trial. BMC cancer. 2010;10:272.
    1. Fong D.Y., Ho J.W., Hui B.P., Lee A.M., Macfarlane D.J., Leung S.S. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ. 2012;344:e70.
    1. Speck R.M., Courneya K.S., Masse L.C., Duval S., Schmitz K.H. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010;4:87–100.
    1. Groeneveldt L., Mein G., Garrod R., Jewell A.P., Van Someren K., Stephens R. A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. BMC cancer. 2013;13:31.
    1. Heinrich M., Fisher A., Paton B., McCourt O., Beeken R.J., Hackshaw A. Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol. BMC cancer. 2016;16:387.
    1. Howell D.A., Smith A.G., Jack A., Patmore R., Macleod U., Mironska E. Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network. BMC Hematol. 2013;13:9.
    1. Craike M., Hose K., Courneya K.S., Harrison S.J., Livingston P.M. Physical activity preferences for people living with multiple myeloma: a qualitative study. Cancer Nurs. 2017;40:E1–E8.
    1. Flory J.H., Mushlin A.I., Goodman Z.I. Proposals to conduct randomized controlled trials without informed consent: a narrative review. J Gen Intern Med. 2016;31:1511–1518.
    1. Schellings R., Kessels A.G., ter Riet G., Sturmans F. The Zelen design may be the best choice for a heroin-provision experiment. J Clin Epidemiol. 1999;52:503–507.
    1. Maddocks M., Mockett S., Wilcock A. Is exercise an acceptable and practical therapy for people with or cured of cancer? A systematic review. Cancer Treat Rev. 2009;35:383–390.
    1. Koutoukidis D.A., Beeken R.J., Manchanda R., Michalopoulou M., Burnell M., Knobf M.T. Recruitment, adherence, and retention of endometrial cancer survivors in a behavioural lifestyle programme: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomised pilot trial. BMJ Open. 2017;7:e018015.
    1. Avins A.L. Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. J Med Ethics. 1998;24:401–408.
    1. Persoon S., Chinapaw M.J.M., Buffart L.M., Brug J., Kersten M.J., Nollet F. Lessons learnt from a process evaluation of an exercise intervention in patients treated with autologous stem cell transplantation. Eur J Cancer Care (Engl) 2018;27
    1. Hertogh E.M., Schuit A.J., Peeters P.H., Monninkhof E.M. Noncompliance in lifestyle intervention studies: the instrumental variable method provides insight into the bias. J Clin Epidemiol. 2010;63:900–906.
    1. Snowdon C., Elbourne D., Garcia J. Zelen randomization: attitudes of parents participating in a neonatal clinical trial. Control Clin Trials. 1999;20:149–171.
    1. Gal R., Monninkhof E.M., van Gils C.H., Groenwold R.H.H., van den Bongard D.H.J.G., Peeters P.H.M. The Trials within Cohorts design faced methodological advantages and disadvantages in the exercise oncology setting. J Clin Epidemiol. 2019;113:137–146.
    1. Kim S.Y., Flory J., Relton C. Ethics and practice of Trials within Cohorts: an emerging pragmatic trial design. Clin Trials. 2018;15:9–16.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj